Novel polymerase inhibitors shape new HCV combinations with telaprevir.
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy / Q000821:virology; D006801:Humans; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D016896:Treatment Outcome
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009842:Oligopeptides; C486464:telaprevir; D012324:RNA-Dependent RNA Polymerase